clinical trial · NCT06314724
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines
Sinovac (Dalian) Vaccine Technology Co., Ltd.·phase3·completed·n = 642
VaricellaVaricella VaccineVarivax
brief summary
This is a Phase Ⅲ, randomized, double-blind, active-controlled study to assess the immunogenicity and safety of the varicella vaccine,Live (hereinafter referred to as "varicella vaccine")manufactured by Sinovac (Dalian) Vaccine Technology Co., LTD.(hereinafter referred to as "Sinovac").
started
Feb 29, 2024
primary completion
Sep 6, 2024
completion
Sep 6, 2024
last updated
Jan 27, 2025
detailed description
A total of 642 healthy participants aged 12\~15 months will be enrolled. All participants will be randomized at a 1:1 ratio to receive a single dose of varicella vaccine either manufactured by Sinovac (Group A) or Merck Sharp \& Dohme (MSD, Group B).
official title
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines: a Randomized, Double-blind, Active-controlled Phase Ⅲ Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol